Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Department of Health and Human Services
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.
Funding
Award size
Not specified
Type
Cooperative Agreement
Dates
Deadline
Later
Posted
05/04/2026
Closes
2026-11-10
Eligibility
Eligibility
Native American tribal governments (Federally recognized)Native American tribal organizations (other than Federally recognized tribal governments)Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationCity or township governmentsFor profit organizations other than small businessesSpecial district governmentsPublic and State controlled institutions of higher educationSmall businessesCounty governmentsNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationState governmentsPrivate institutions of higher educationIndependent school districtsPublic housing authorities/Indian housing authoritiesOthers (see text field entitled "Additional Information on Eligibility" for clarification)
Program
Funding area
Health - HL
Opportunity #
RFA-NS-26-001
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov